About this Journal Submit a Manuscript Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 212178, 8 pages
http://dx.doi.org/10.1100/2012/212178
Review Article

Mechanisms, Risk Factors, and Management of Acquired Long QT Syndrome: A Comprehensive Review

Department of Cardiology, University Hospital of Heraklion, 711 10 Heraklion, Crete, Greece

Received 31 October 2011; Accepted 22 December 2011

Academic Editors: H. Kitabata and S. Sun

Copyright © 2012 Eleftherios M. Kallergis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Selzer and H. W. Wray, “Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias,” Circulation, vol. 30, pp. 17–26, 1964.
  2. F. Dessertenne, “Ventricular tachycardia with 2 variable opposing foci,” Archives des Maladies du Coeur et des Vaisseaux, vol. 59, no. 2, pp. 263–272, 1966. View at Scopus
  3. K. E. Lasser, P. D. Allen, S. J. Woolhandler, D. U. Himmelstein, S. M. Wolfe, and D. H. Bor, “Timing of new black box warnings and withdrawals for prescription medications,” Journal of the American Medical Association, vol. 287, no. 17, pp. 2215–2220, 2002. View at Scopus
  4. T. Sadanaga, F. Sadanaga, H. Yao, and M. Fujishima, “An evaluation of ECG leads used to assess QT prolongation,” Cardiology, vol. 105, no. 3, pp. 149–154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. H. Indik, E. C. Pearson, K. Fried, and R. L. Woosley, “Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval,” Heart Rhythm, vol. 3, no. 9, pp. 1003–1007, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Reardon and M. Malik, “QT interval change with age in an overtly healthy older population,” Clinical Cardiology, vol. 19, no. 12, pp. 949–952, 1996. View at Scopus
  7. B. Surawicz, T. Knilans, and T.-C. Chou, Chou’s Electrocardiography in Clinical Practice, W.B. Saunders Company, Philadelphia, Pa, USA, 2001.
  8. J. Morganroth, F. V. Brozovich, J. T. McDonald, and R. A. Jacobs, “Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia,” American Journal of Cardiology, vol. 67, no. 8, pp. 774–776, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Molnar, F. Zhang, J. Weiss, F. A. Ehlert, and J. E. Rosenthal, “Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events,” Journal of the American College of Cardiology, vol. 27, no. 1, pp. 76–83, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Sanguinetti and N. K. Jurkiewicz, “Two components of cardiac delayed rectifier K+ current: differential sensitivity to block by class III antiarrhythmic agent,” Journal of General Physiology, vol. 96, no. 1, pp. 195–215, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. M. C. Sanguinetti and N. K. Jurkiewicz, “Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 260, no. 2, pp. H393–H399, 1991. View at Scopus
  12. G. A. Gintant, “Two components of delayed rectifier current in canine atrium and ventricle: does IKs play a role in the reverse rate dependence of class III agents?” Circulation Research, vol. 78, no. 1, pp. 26–37, 1996. View at Scopus
  13. M. C. Sanguinetti, N. K. Kurkiewicz, A. Scott, and P. K. S. Siegl, “Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: mechanism of action,” Circulation Research, vol. 68, no. 1, pp. 77–84, 1991. View at Scopus
  14. N. K. Jurkiewicz and M. C. Sanguinetti, “Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of rapidly activating delayed rectifier K+ current by dofetilide,” Circulation Research, vol. 72, no. 1, pp. 75–83, 1993. View at Scopus
  15. M. C. Sanguinetti, M. E. Curran, A. Zou et al., “Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel,” Nature, vol. 384, no. 6604, pp. 80–83, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Barhanin, F. Lesage, E. Guillemare, M. Fink, M. Lazdunski, and G. Romey, “K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current,” Nature, vol. 384, no. 6604, pp. 78–80, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. D. M. Roden and P. C. Viswanathan, “Genetics of acquired long QT syndrome,” The Journal of Clinical Investigation, vol. 115, pp. 2025–2032, 2005, A comprehensive review of molecular and cellular mechanisms underlying acquired LQTS.
  18. M. E. Curran, I. Splawski, K. W. Timothy, G. M. Vincent, E. D. Green, and M. T. Keating, “A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome,” Cell, vol. 80, no. 5, pp. 795–803, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Sanguinetti and M. Tristani-Firouzi, “hERG potassium channels and cardiac arrhythmia,” Nature, vol. 440, pp. 463–469, 2006, Expert review of the role of KCNH2 in arrhythmias, in both congenital and drug induced LQTS.
  20. D. Fernandez, A. Ghanta, G. W. Kauffman, and M. C. Sanguinetti, “Physicochemical Features of the hERG Channel Drug Binding Site,” Journal of Biological Chemistry, vol. 279, no. 11, pp. 10120–10127, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. M. Roden, R. Lazzara, M. Rosen, P. J. Schwartz, J. Towbin, and G. Michael Vincent, “Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions,” Circulation, vol. 94, no. 8, pp. 1996–2012, 1996. View at Scopus
  22. C. Antzelevitch, “Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes,” Heart Rhythm, vol. 2, no. 11, pp. S9–S15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. G. Yap and A. J. Camm, “Drug induced QT prolongation and torsades de pointes,” Heart, vol. 89, no. 11, pp. 1363–1372, 2003. View at Scopus
  24. C. D. Swerdlow, D. J. Martin, R. M. Kass et al., “The zone of vulnerability to T wave shocks in humans,” Journal of Cardiovascular Electrophysiology, vol. 8, no. 2, pp. 145–154, 1997. View at Scopus
  25. J. T. Y. Hii, D. G. Wyse, A. M. Gillis, H. J. Duff, M. A. Solylo, and L. B. Mitchell, “Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone,” Circulation, vol. 86, no. 5, pp. 1376–1382, 1992. View at Scopus
  26. R. R. Shah, “Drug-induced QT dispersion: does it predict the risk of torsade de pointes?” Journal of Electrocardiology, vol. 38, no. 1, pp. 10–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Antzelevitch, “Tpeak-Tend interval as an index of transmural dispersion of repolarization,” European Journal of Clinical Investigation, vol. 31, no. 7, pp. 555–557, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Antzelevitch, “Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 4, pp. H2024–H2038, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Antzelevitch, “Heterogeneity and cardiac arrhythmias: an overview,” Heart Rhythm, vol. 4, no. 7, pp. 964–972, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Topilski, O. Rogowski, R. Rosso et al., “The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias,” Journal of the American College of Cardiology, vol. 49, no. 3, pp. 320–328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Yamaguchi, M. Shimizu, H. Ino et al., “T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity,” Clinical Science, vol. 105, no. 6, pp. 671–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Xia, Y. Liang, O. Kongstad et al., “In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine,” Heart Rhythm, vol. 2, no. 2, pp. 162–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Emori and C. Antzelevitch, “Cellular basis for complex T waves and arrhythmic activity following combined IKr and IKs block,” Journal of Cardiovascular Electrophysiology, vol. 12, no. 12, pp. 1369–1378, 2001. View at Scopus
  34. M. Grabowski, G. Karpinski, K. J. Filipiak, and G. Opolski, “Images in cardiovascular medicine. Drug-induced long-QT syndrome with macroscopic T-wave alternans,” Circulation, vol. 110, no. 18, pp. 459–460, 2004. View at Scopus
  35. W. Shimizu and C. Antzelevitch, “Cellular and ionic basis for T-wave alternans under long-QT conditions,” Circulation, vol. 99, no. 11, pp. 1499–1507, 1999. View at Scopus
  36. P. Kirchhof, M. R. Franz, A. Bardai, and A. M. Wilde, “Giant T-U waves precede torsades de pointes in long QT syndrome. A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation,” Journal of the American College of Cardiology, vol. 54, no. 2, pp. 143–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Hinterseer, M. B. Thomsen, B. M. Beckmann et al., “Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study,” European Heart Journal, vol. 29, no. 2, pp. 185–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. D. M. Roden, R. L. Woosley, and R. K. Primm, “Incidence and clinical feature of the quinidine-associated long QT syndrome: implications for patient care,” American Heart Journal, vol. 111, no. 6, pp. 1088–1093, 1986. View at Scopus
  39. R. R. Makkar, B. S. Fromm, R. T. Steinman, M. D. Meissner, and M. H. Lehmann, “Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs,” Journal of the American Medical Association, vol. 270, no. 21, pp. 2590–2597, 1993. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Rautaharju, S. H. Zhou, S. Wong et al., “Sex differences in the evolution of the electrocardiographic QT interval with age,” Canadian Journal of Cardiology, vol. 8, no. 7, pp. 690–695, 1992. View at Scopus
  41. A. Arya, “Gender-related differences in ventricular repolarization: beyond gonadal steroids,” Journal of Cardiovascular Electrophysiology, vol. 16, no. 5, pp. 525–527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Yang, D. J. Snyders, and D. M. Roden, “Rapid inactivation determines the rectification and [K+](o) dependence of the rapid component of the delayed rectifier K+ current in cardiac cells,” Circulation Research, vol. 80, no. 6, pp. 782–789, 1997. View at Scopus
  43. H. Numaguchi, J. P. Johnson Jr., C. I. Petersen, and J. R. Balser, “A sensitive mechanism for cation modulation of potassium current,” Nature Neuroscience, vol. 3, no. 5, pp. 429–430, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Yang and D. M. Roden, “Extracellular potassium modulation of drug block of IKr: implications for torsade de pointes and reverse use-dependence,” Circulation, vol. 93, no. 3, pp. 407–411, 1996. View at Scopus
  45. A. M. Choy, C. C. Lang, D. M. Chomsky, G. H. Rayos, J. R. Wilson, and D. M. Roden, “Normalization of acquired QT prolongation in humans by intravenous potassium,” Circulation, vol. 96, no. 7, pp. 2149–2154, 1997. View at Scopus
  46. S. P. Etheridge, S. J. Compton, M. Tristani-Firouzi, and J. W. Mason, “A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations,” Journal of the American College of Cardiology, vol. 42, no. 10, pp. 1777–1782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. D. M. Roden and M. E. Anderson, “The pause that refreshes, or does it? Mechanisms in torsades de pointes,” Heart, vol. 84, no. 3, pp. 235–237, 2000. View at Scopus
  48. E. H. Locati, P. Maison-Blanche, P. Dejode, B. Cauchemez, and P. Coumel, “Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings,” Journal of the American College of Cardiology, vol. 25, no. 7, pp. 1564–1575, 1995. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Darbar, P. Harris, A. Hardy, et al., “Marked steepening of QT restitution following cardioversion of atrial fibrillation,” Heart Rhythm, vol. 1, p. S192, 2004.
  50. A. M. J. Choy, D. Darbar, S. Dell'Orto, and D. M. Roden, “Exaggerated QT prolongation after cardioversion of atrial fibrillation,” Journal of the American College of Cardiology, vol. 34, no. 2, pp. 396–401, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Torp-Pedersen, M. Møller, P. E. Bloch-Thomsen et al., “Dofetilide in patients with congestive heart failure and left ventricular dysfunction,” The New England Journal of Medicine, vol. 341, no. 12, pp. 857–865, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. K. R. Wyse, V. Ye, and T. J. Campbell, “Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity,” Journal of Cardiovascular Pharmacology, vol. 21, no. 2, pp. 316–322, 1993. View at Scopus
  53. E. Drouin, G. Lande, and F. Charpentier, “Amiodarone reduces transmural heterogeneity of repolarization in the human heart,” Journal of the American College of Cardiology, vol. 32, no. 4, pp. 1063–1067, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. S. H. Hohnloser, T. Klingenheben, and B. N. Singh, “Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia,” Annals of Internal Medicine, vol. 121, no. 7, pp. 529–535, 1994. View at Scopus
  55. V. R. Vorperian, T. C. Havighurst, S. Miller, and C. T. January, “Adverse effects of low dose amiodarone: a meta-analysis,” Journal of the American College of Cardiology, vol. 30, no. 3, pp. 791–801, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Lazzara, “Antiarrhythmic drugs and torsade de pointes,” European Heart Journal, vol. 14, pp. 88–92, 1993. View at Scopus
  57. K. A. Ellenbogen, B. S. Stambler, and M. A. Wood, “Efficacy of intravenous inbutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study,” Journal of the American College of Cardiology, vol. 28, no. 4, pp. 130–136, 1996. View at Scopus
  58. B. S. Stambler, M. A. Wood, K. A. Ellenbogen, K. T. Perry, L. K. Wakefield, and J. T. VanderLugt, “Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators,” Circulation, vol. 94, no. 7, pp. 1613–1621, 1996. View at Scopus
  59. S. Zhang, Z. Zhou, Q. Gong, J. C. Makielski, and C. T. January, “Mechanism of block and identification of the verapamil binding domain to HERG potassium channels,” Circulation Research, vol. 84, no. 9, pp. 989–998, 1999. View at Scopus
  60. W. Shimizu, T. Ohe, T. Kurita et al., “Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome,” Journal of the American College of Cardiology, vol. 26, no. 5, pp. 1299–1309, 1995. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Aiba, W. Shimizu, M. Inagaki et al., “Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil,” Journal of the American College of Cardiology, vol. 45, no. 2, pp. 300–307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Napolitano, P. J. Schwartz, A. M. Brown et al., “Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias,” Journal of Cardiovascular Electrophysiology, vol. 11, no. 6, pp. 691–696, 2000. View at Scopus
  63. P. Yang, H. Kanki, B. Drolet et al., “Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes,” Circulation, vol. 105, no. 16, pp. 1943–1948, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. S. G. Priori, C. Napolitano, and P. J. Schwartz, “Low penetrance in the long-QT syndrome clinical impact,” Circulation, vol. 99, no. 4, pp. 529–533, 1999. View at Scopus
  65. S. G. Priori, P. J. Schwartz, C. Napolitano et al., “Risk stratification in the long-QT syndrome,” The New England Journal of Medicine, vol. 348, no. 19, pp. 1866–1874, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. P. J. Kannankeril, D. M. Roden, K. J. Norris, S. P. Whalen, A. L. George, and K. T. Murray, “Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives,” Heart Rhythm, vol. 2, no. 2, pp. 134–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. D. M. Roden, “Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes,” Pacing and Clinical Electrophysiology, vol. 21, no. 5, pp. 1029–1034, 1998. View at Scopus
  68. A. D. C. Paulussen, R. A. H. J. Gilissen, M. Armstrong et al., “Genetic variations of HCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients,” Journal of Molecular Medicine, vol. 82, no. 3, pp. 182–188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. A. R. Mank-Seymour, J. L. Richmond, L. S. Wood et al., “Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes,” American Heart Journal, vol. 152, no. 6, pp. 1116–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Jost, L. Virag, M. Bitay, et al., “Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle,” Circulation, vol. 112, pp. 1392–1399, 2005.
  71. J. Silva and Y. Rudy, “Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve,” Circulation, vol. 112, no. 10, pp. 1384–1391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. M. C. Sanguinetti, N. K. Kurkiewicz, A. Scott, and P. K. S. Siegl, “Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: mechanism of action,” Circulation Research, vol. 68, no. 1, pp. 77–84, 1991. View at Scopus
  73. Y. Habuchi, H. Tanaka, T. Furukawa, Y. Tsujimura, H. Takahashi, and M. Yoshimura, “Endothelin enhances delayed potassium current via phospholipase C in guinea pig ventricular myocytes,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 262, no. 2, pp. 345–354, 1992. View at Scopus
  74. L. Xiao, J. Xiao, X. Luo, H. Lin, Z. Wang, and S. Nattel, “Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve,” Circulation, vol. 118, no. 10, pp. 983–992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Splawski, K. W. Timothy, M. Tateyama et al., “Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia,” Science, vol. 297, no. 5585, pp. 1333–1336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. M. J. Ackerman, D. J. Tester, G. S. Jones, M. L. Will, C. R. Burrow, and M. E. Curran, “Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome,” Mayo Clinic Proceedings, vol. 78, no. 12, pp. 1479–1487, 2003. View at Scopus
  77. S. H. Koo, W. F. Ho, and E. J. D. Lee, “Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore,” British Journal of Clinical Pharmacology, vol. 61, no. 3, pp. 301–308, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. C. R. Bezzina, W. Shimizu, P. Yang et al., “Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction,” Circulation, vol. 113, no. 3, pp. 338–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. P. T. Fitzgerald and M. J. Ackerman, “Drug-induced torsades de pointes: the evolving role of pharmacogenetics,” Heart Rhythm, vol. 2, no. 11, pp. S30–S37, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. P. T. Nguyen, M. M. Scheinman, and J. Seger, “Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval,” Circulation, vol. 74, no. 2, pp. 340–349, 1986. View at Scopus
  81. R. B. Vukmir and K. L. Stein, “Torsades de pointes therapy with phenytoin,” Annals of Emergency Medicine, vol. 20, no. 2, pp. 198–200, 1991. View at Scopus
  82. S. Banai and D. Tzivoni, “Drug therapy for torsade de pointes,” Journal of Cardiovascular Electrophysiology, vol. 4, no. 2, pp. 206–210, 1993. View at Scopus
  83. I. A. Khan, “Clinical and therapeutic aspects of congenital and acquired long QT syndrome,” American Journal of Medicine, vol. 112, no. 1, pp. 58–66, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. B. P. Damiano and M. R. Rosen, “Effects of pacing on triggered activity induced by early afterdepolarizations,” Circulation, vol. 69, no. 5, pp. 1013–1025, 1984. View at Scopus
  85. S. Viskin, “Torsades de pointes,” Current Treatment Options in Cardiovascular Medicine, vol. 1, pp. 187–195, 1999.
  86. S. Viskin, “Cardiac pacing in the long QT syndrome: review of available data and practical recommendations,” Journal of Cardiovascular Electrophysiology, vol. 11, no. 5, pp. 593–600, 2000. View at Scopus